ReviewHuman
LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
Pharmacological reports : PR, 2016 Aug. Fabisiak A, Murawska N, Fichna J.
Study type
Review
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Pharmacological reports : PR
Published
2016 Aug
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Anti-Infective AgentsAntimicrobial Cationic PeptidesCommunicable DiseasesGastrointestinal DiseasesHumansImmune System DiseasesRespiratory Tract InfectionsSkinCathelicidins
Other papers on LL-37
Randomized controlled trial · 2021
Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Randomized controlled trial · 2014Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Journal article · 2006The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page